The only Dwight Evans making noise on social media this week played outfield for the Boston Red Sox in the 1970s and 80s. The other one, Pennsylvania's 3rd District Democrat, sits on the House Ways and Means Committee, voted on a stack of banking bills in May, and has filed five stock sale disclosures in the last 90 days. One of those sales touches a sector that falls directly inside his committee's jurisdiction. His 30-day alpha across eight scored trades is negative 5.7 percent. He is 0 for 8. The market is not impressed. Neither are we.
The Social Graph Is Talking About a Different Dwight Evans
Three posts on Bluesky this week. All of them about a guy who hit 256 home runs in the American League during the 1980s. Vintage photos. Box scores. Wax packs. Not a single mention of the congressman from Philadelphia.
That's the baseline. When the most relevant social conversation about a sitting member of Congress is nostalgic baseball content, the member has, charitably, a visibility problem. Less charitably, it means the financial disclosures are doing more talking than the press shop is.
So let's read the disclosures.
Five Sales, One Spring, Zero Winners
Between March 24 and May 11 of this year, Evans filed five sale transactions, all in the $1,000-to-$50,000 range. The full list:
- March 24: Micron Technology (MU), $15K-$50K, sold.
- May 7: Intel (INTC), $1K-$15K, sold.
- May 7: Quanta Services (PWR), $1K-$15K, sold.
- May 7: Thermo Fisher Scientific (TMO), $1K-$15K, sold.
- May 11: American Tower (AMT), $1K-$15K, sold.
Three trades dropped on the same day. That's not unusual. What's unusual is the batting average: across his full scored sample of eight trades on file, Evans is 0 for 8 on 30-day alpha. Eight trades. Zero that beat the S&P 500 over the following month. Mean alpha: negative 5.7 percent.
The best trade in the sample, on that record, is the American Tower sale on May 11. Its 30-day alpha is negative 0.0 percent. Flat. That's the winner.
The Thermo Fisher Trade Is the One Worth Watching
Most of these trades are just trades. No committee overlap, no flagged timing, nothing to connect them to Evans's legislative work beyond the coincidence of timing. Micron is a semiconductor company. Quanta Services builds power infrastructure. American Tower runs cell towers. Evans sits on Ways and Means. None of those sectors land in Ways and Means jurisdiction.
The Thermo Fisher sale is different.
Thermo Fisher Scientific is one of the largest life sciences and medical equipment companies in the world. The May 7 sale, in the $1,000-to-$15,000 range, carries a committee overlap flag: Healthcare. Evans's committee assignments include the House Committee on Ways and Means, Health subcommittee. Healthcare spending, Medicare reimbursement rates, drug pricing policy: those are squarely in his lane.
The 30-day alpha on that sale was negative 7.8 percent. Thermo Fisher moved against him. He sold, and the stock outperformed the index in the following 30 days. If the goal was to get ahead of something bad, the something bad didn't materialize on that timeline. The receipts are public. Make of them what you make of them.
The committee overlap doesn't make the trade improper. Members are required to disclose. They are not required to divest, recuse, abstain, blush, or explain themselves. But a Ways and Means Health subcommittee member selling a major healthcare equipment company is the kind of data point that earns a second look, and Blind Trust's job is to provide the second look.
The Alpha Record Is a Whole Conversation on Its Own
Let's be precise about what 0-for-8 means and what it doesn't.
Eight scored trades. Zero positive 30-day alpha. Mean of negative 5.7 percent per trade. The worst single trade in the sample is the Micron sale from March 24: negative 14.1 percent alpha over the following 30 days. He sold $15,000-to-$50,000 worth of Micron, and Micron then outran the S&P by 14 points in the next month.
The second-worst: Thermo Fisher at negative 7.8 percent. Third-worst: Quanta Services at negative 7.7 percent, also sold on May 7.
This is not evidence of anything except bad timing, or possibly a very conservative sell discipline that keeps getting wrong-footed by the market. Eight trades is not a large enough sample to draw conclusions about skill or the absence of it. What it is: a consistent directional miss. Every single scored trade in the sample sold before a 30-day outperformance. The market went up after Evans sold. Every time. For now.
The Intel sale on May 7 is the second-best result in the sample at negative 1.5 percent alpha. Intel has been a complicated story all year. Quanta Services, the power infrastructure play, came in at negative 7.7 percent. Quanta builds electrical grid infrastructure and data center power systems. The AI infrastructure buildout has been one of the stronger trades of the last 18 months. Evans sold in May. The clock started ticking.
The Banking Votes Are a Separate Track
On May 20, Evans voted Yea on a cluster of banking legislation: the American Access to Banking Act, the Community Bank Deposit Access Act of 2025, and the Keeping Deposits Local Act. All three passed. All three carry meaningful market relevance scores.
None of that is a Ways and Means story. Bank regulation lives at the House Financial Services Committee. Evans is not on Financial Services. Floor votes on banking bills are floor votes, not oversight windows, and we won't imply otherwise. He voted yes on bills that passed. That's the record.
On June 11, he voted Nay on reauthorization of FISA surveillance authorities. That bill failed. His side won that one. None of his disclosed trades touch surveillance technology or defense contractors in the flagged period, so there's nothing to cross-reference there.
The vote-trade overlap table for Evans is empty. No flagged timing where a trade and a vote share a close enough date to draw a line between them. The trades and the votes exist on separate tracks, at least for now.
What the Filings Actually Tell You
Here's the picture the disclosures paint: a Ways and Means member who has been steadily reducing equity exposure through the spring of 2026, selling across semiconductors, infrastructure, healthcare equipment, telecom REITs, and power grid plays. Small positions, mostly $1,000-to-$15,000 range, with one larger Micron position at up to $50,000. All sales. No purchases disclosed in the 90-day window.
The consistent selling could mean a lot of things. Portfolio rebalancing. Cash needs. A generally bearish view on equities. A financial advisor making decisions the member doesn't think about twice. The disclosures don't tell you which. They tell you the dates, the tickers, and the ranges.
What the alpha record adds is the market's verdict on the timing: so far, negative. The positions Evans exited kept running. That's eight trades. Eight misses. A mean of negative 5.7 percent. The Thermo Fisher trade is the only one that carries a committee flag, and even that one moved against him after the sale.
The institutional deadpan version of this story: a member of Congress with healthcare oversight responsibilities sold a healthcare equipment stock, disclosed it on time, and then watched the stock outperform. The disclosure system worked exactly as designed. Whether the system is designed correctly is a question for a different article, and a different Congress.
Dwight Evans the congressman has five disclosures and an 0-for-8 alpha record. Dwight Evans the Red Sox outfielder led the American League in home runs across the entire 1980s decade. One of these men is having a better week on social media. The full filing record is here.